JPH01308232A - 固型医薬およびその製造法 - Google Patents

固型医薬およびその製造法

Info

Publication number
JPH01308232A
JPH01308232A JP63137925A JP13792588A JPH01308232A JP H01308232 A JPH01308232 A JP H01308232A JP 63137925 A JP63137925 A JP 63137925A JP 13792588 A JP13792588 A JP 13792588A JP H01308232 A JPH01308232 A JP H01308232A
Authority
JP
Japan
Prior art keywords
vitamin
atp
solid
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63137925A
Other languages
English (en)
Japanese (ja)
Inventor
Tadashi Makino
正 槙野
Koji Doi
光司 土井
Masayoshi Matsuoka
松岡　昌義
Toshiji Tsuboi
坪井　利治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SENJIYU SEIYAKU KK
Senju Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Original Assignee
SENJIYU SEIYAKU KK
Senju Pharmaceutical Co Ltd
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SENJIYU SEIYAKU KK, Senju Pharmaceutical Co Ltd, Takeda Chemical Industries Ltd filed Critical SENJIYU SEIYAKU KK
Priority to JP63137925A priority Critical patent/JPH01308232A/ja
Priority to AT89110019T priority patent/ATE74768T1/de
Priority to US07/360,869 priority patent/US5017564A/en
Priority to EP89110019A priority patent/EP0348688B1/en
Priority to DE8989110019T priority patent/DE68901216D1/de
Priority to ES198989110019T priority patent/ES2032628T3/es
Priority to KR1019890007676A priority patent/KR910000163A/ko
Publication of JPH01308232A publication Critical patent/JPH01308232A/ja
Priority to GR920400812T priority patent/GR3004440T3/el
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP63137925A 1988-06-03 1988-06-03 固型医薬およびその製造法 Pending JPH01308232A (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP63137925A JPH01308232A (ja) 1988-06-03 1988-06-03 固型医薬およびその製造法
AT89110019T ATE74768T1 (de) 1988-06-03 1989-06-02 Feste pharmazeutische zubereitung und verfahren zur herstellung derselben.
US07/360,869 US5017564A (en) 1988-06-03 1989-06-02 Solid pharmaceutical preparation and method of producing same
EP89110019A EP0348688B1 (en) 1988-06-03 1989-06-02 Solid pharmaceutical preparation and method of producing same
DE8989110019T DE68901216D1 (de) 1988-06-03 1989-06-02 Feste pharmazeutische zubereitung und verfahren zur herstellung derselben.
ES198989110019T ES2032628T3 (es) 1988-06-03 1989-06-02 Metodo para producir una preparacion farmaceutica solida.
KR1019890007676A KR910000163A (ko) 1988-06-03 1989-06-03 고형 약학제제 및 이의 제조방법
GR920400812T GR3004440T3 (enExample) 1988-06-03 1992-04-22

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63137925A JPH01308232A (ja) 1988-06-03 1988-06-03 固型医薬およびその製造法

Publications (1)

Publication Number Publication Date
JPH01308232A true JPH01308232A (ja) 1989-12-12

Family

ID=15209888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63137925A Pending JPH01308232A (ja) 1988-06-03 1988-06-03 固型医薬およびその製造法

Country Status (8)

Country Link
US (1) US5017564A (enExample)
EP (1) EP0348688B1 (enExample)
JP (1) JPH01308232A (enExample)
KR (1) KR910000163A (enExample)
AT (1) ATE74768T1 (enExample)
DE (1) DE68901216D1 (enExample)
ES (1) ES2032628T3 (enExample)
GR (1) GR3004440T3 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030030883A (ko) * 2001-10-12 2003-04-18 에스에스 세야쿠 가부시키 가이샤 피로 회복 의약 조성물
WO2007138748A1 (ja) * 2006-05-30 2007-12-06 Kowa Co., Ltd. 疲労回復のための医薬
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
JP5032310B2 (ja) * 2005-05-27 2012-09-26 興和株式会社 疲労回復のための医薬
JP2022531663A (ja) * 2019-05-06 2022-07-08 フエルレル インターナショナル，ソシエダッド アノニマ ピリミジン及び／またはプリン誘導体とビタミンｂを含む多層医薬または栄養補助固形剤形、その調製及び使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634374B1 (fr) * 1988-07-19 1993-10-15 Laboratoires Serobiologiques Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
AU8028600A (en) * 1999-10-20 2001-04-30 Eliezer Rapaport Methods, pharmaceutical and therapeutic compositions for administering adenosine
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US20030069203A1 (en) * 2001-06-04 2003-04-10 Lee Steve S. Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
US20050070701A1 (en) * 2003-09-29 2005-03-31 Hochstetler Spencer Erich Detection of living cells in polymers or pigments
ITMI20041772A1 (it) * 2004-09-17 2004-12-17 Bioprogress Spa Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.
EP3875092B1 (en) * 2018-11-02 2025-11-19 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2775521A (en) * 1953-09-29 1956-12-25 Hoffmann La Roche Method of fortifying grain products and the resulting product
US3037911A (en) * 1959-09-04 1962-06-05 Merck & Co Inc Chewable, palatable, vitamin b preparations
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
SE352811B (enExample) * 1971-06-04 1973-01-15 Pharmacia Ab
GB1431841A (en) * 1973-01-15 1976-04-14 Evans S C Ophthalmic-nutritional preparations
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
FR2358155A1 (fr) * 1976-07-15 1978-02-10 Lapinet Eugene Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
US4382924A (en) * 1980-06-25 1983-05-10 The Procter & Gamble Company Palatable composition containing oil or oil-like materials
FR2557452B1 (fr) * 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US4764388A (en) * 1985-01-25 1988-08-16 Nabisco Brands, Inc. Method for making vitamin enriched cereal
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030030883A (ko) * 2001-10-12 2003-04-18 에스에스 세야쿠 가부시키 가이샤 피로 회복 의약 조성물
JP5032310B2 (ja) * 2005-05-27 2012-09-26 興和株式会社 疲労回復のための医薬
WO2007138748A1 (ja) * 2006-05-30 2007-12-06 Kowa Co., Ltd. 疲労回復のための医薬
JP5114394B2 (ja) * 2006-05-30 2013-01-09 興和株式会社 疲労回復のための医薬
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
JP5114399B2 (ja) * 2006-06-27 2013-01-09 興和株式会社 疲労予防及び／又は回復のための医薬
JP2022531663A (ja) * 2019-05-06 2022-07-08 フエルレル インターナショナル，ソシエダッド アノニマ ピリミジン及び／またはプリン誘導体とビタミンｂを含む多層医薬または栄養補助固形剤形、その調製及び使用
TWI827736B (zh) * 2019-05-06 2024-01-01 西班牙商菲洛國際股份公司 包含嘧啶及/或嘌呤衍生物及維生素b的多層醫藥或類藥劑營養固體劑型、其製備及用途

Also Published As

Publication number Publication date
ES2032628T3 (es) 1993-02-16
ATE74768T1 (de) 1992-05-15
KR910000163A (ko) 1991-01-29
GR3004440T3 (enExample) 1993-03-31
US5017564A (en) 1991-05-21
EP0348688A1 (en) 1990-01-03
EP0348688B1 (en) 1992-04-15
DE68901216D1 (de) 1992-05-21

Similar Documents

Publication Publication Date Title
EP2057984B1 (de) Retardtabletten mit Hydromorphon
DE3880762T2 (de) Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung.
DE69901570T2 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
DE60221691T3 (de) Tamsulosin tabletten ohne nahrungsmitteleffekt
DE60115870T2 (de) Niedrig dosierte entecavir-formulierung und deren verwendung
US7074417B2 (en) Multiple-delayed release anti-viral product, use and formulation thereof
JPH01308232A (ja) 固型医薬およびその製造法
CN111728953B (zh) 一种托法替布或其盐的缓释制剂及其制备方法
JPH01308231A (ja) 安定化された医薬組成物および製造法
EP0299211A1 (de) DHP-Manteltablette
DE102004062475A1 (de) Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE69817848T2 (de) Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus
US20070202172A1 (en) Metoprolol succinate E.R. tablets and methods for their preparation
KR20030011805A (ko) 스타부딘을 함유하는 서방성 비들렛
US20120003307A1 (en) Levetiracetam controlled release composition
CZ287563B6 (en) Pharmaceutical preparations for treating hyperglycemia
JP5822758B2 (ja) 速溶性防湿フィルムコーティング製剤及びその製造方法
DE19850445A1 (de) Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
CA2531486A1 (en) Saquinavir mesylate oral dosage form
JPH04103525A (ja) 難水溶性薬物の持続性製剤化方法
EP3459531B1 (de) Verfahren zur herstellung einer schichttablette
JPH0797330A (ja) 経口コレステロール低下剤
DE602006000402T2 (de) Stabile Zubereitung enthaltend eine feuchtigkeitsemphindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.
CN102397262A (zh) 阿莫西林缓释固体药物组合物及其制备方法
EP1983967A2 (de) Schnell freisetzende irbesartan-haltige pharmazeutische zusammensetzung